FDA Press Release Policy Restricts Free Speech, Needs Revision – PhRMA
Executive Summary
FDA should reconsider its policies restricting language in press releases on unapproved drug uses in light of First Amendment rights, the Pharmaceutical Research & Manufacturers of America maintains in comments to the agency
You may also be interested in...
DTC Ads Should Cite Range Of Treatment Options, Blue Cross Assoc. Tells FDA
Direct-to-consumer advertising should include disclosures to note when a particular drug is one of a range of available treatment choices, the Blue Cross and Blue Shield Association said in comments to FDA
Avage Approval For Wrinkles Complements Botox Cosmetic, Allergan Says
Allergan is highlighting the complementary nature of its wrinkle cream Avage to the injectable wrinkle therapy Botox Cosmetic following FDA approval of Avage (tazarotene) Sept. 30
DTC Ads Should Cite Range Of Treatment Options, Blue Cross Assoc. Tells FDA
Direct-to-consumer advertising should include disclosures to note when a particular drug is one of a range of available treatment choices, the Blue Cross and Blue Shield Association said in comments to FDA